Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY - FEDBIZOPPS ISSUE OF AUGUST 10, 2013 FBO #4277
MODIFICATION

A -- FDA_13-RFQ-1120926

Notice Date
8/8/2013
 
Notice Type
Modification/Amendment
 
NAICS
541712 — Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
 
Contracting Office
Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
 
ZIP Code
20857-0001
 
Solicitation Number
13-RFQ-1120926
 
Archive Date
8/20/2013
 
Point of Contact
Aaron A. Glazier, Phone: 8705437577
 
E-Mail Address
aaron.glazier@fda.hhs.gov
(aaron.glazier@fda.hhs.gov)
 
Small Business Set-Aside
N/A
 
Description
The purpose of this amendment is to provide a response to the following vendor question posed on 8/7/13: "We interpret that the generic in question (Budeprion XL 300 mg) will not be part of the described study and that we will obtain clinical trial material directly from suppliers as part of the total cost of the study. Please confirm." Govt Response: Budeprion XL 300 mg will not be part of the study because it has been withdrawn from the market. The vendor should obtain clinical trial materials directly from suppliers as part of the total cost of the study. No extension to the bid deadline will be issued.
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/13-RFQ-1120926/listing.html)
 
Place of Performance
Address: Contractor's Place of Business, United States
 
Record
SN03143203-W 20130810/130809000343-4eed8528a3b72813cd84b664acb5e9f4 (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.